

Susan M. Sharko, Esq. (NJ ID No. 009971979)
Jessica L. Brennan, Esq. (NJ ID No. 024892007)
DRINKER BIDDLE & REATH LLP
A Delaware Limited Liability Partnership
600 Campus Drive
Florham Park, New Jersey 07932-1047
(973) 549-7000
Attorneys for Defendants
JOHNSON & JOHNSON, JANSSEN RESEARCH & DEVELOPMENT, LLC,
and JANSSEN PHARMACEUTICALS, INC.

FILED
NOV 03 2017
Judge James F. Hyland

#0646
10/27/17

PHYLLIS BEATO,

Plaintiff,

v.

JOHNSON & JOHNSON, JANSSEN
RESEARCH & DEVELOPMENT, LLC
and JANSSEN PHARMACEUTICALS, INC.,

Defendants.

SUPERIOR COURT OF NEW JERSEY
LAW DIVISION: MIDDLESEX COUNTY
DOCKET NO. MID-L-9796-14

**LEVAQUIN LITIGATION
CASE CODE 286**

CIVIL ACTION

**ORDER DISMISSING PLAINTIFFS'
COMPLAINT WITHOUT PREJUDICE
PURSUANT TO CMO 11**

THIS MATTER having been opened to the Court by Drinker Biddle & Reath LLP, attorneys for defendants Johnson & Johnson, Janssen Research & Development, LLC, and Janssen Pharmaceuticals, Inc., for an entry of an Order dismissing plaintiff's Complaint without prejudice pursuant to Case Management Order No. 11, and the Court having considered the submissions of the parties, and for good cause having been shown:


IT IS on this 2nd day of November, 2017

ORDERED as follows:

1. The Motion of defendants Johnson & Johnson, Janssen Research & Development, LLC, and Janssen Pharmaceuticals, Inc. to dismiss Plaintiff's Complaint without prejudice pursuant to Case Management Order No. 11, be and hereby is granted;

2. Plaintiff's Complaint is hereby dismissed without prejudice, and can only be reinstated by motion to the court stating that the failure has been corrected and that a \$100 fine has been paid if filed within 30 days. A \$300 fine shall be required for reinstatement after 30 days from the date of this order. After 90 days, the defendants may move to dismiss with prejudice if no motion to reinstate has been filed; and

3. A true copy of this Order shall be served upon plaintiff within 10 days of its receipt by counsel for Defendants Johnson & Johnson, Janssen Research & Development, LLC, and Janssen Pharmaceuticals, Inc.



Honorable James F. Hyland, J.S.C.

This motion was:

_____ Opposed

_____ Unopposed